Linda C. Burkly
Executive VP & Chief Scientific OfficerDr. Linda C. Burkly, Ph.D., is Executive VP & Chief Scientific Officer of Editas Medicine, Inc. from July 2023. Prior to joining Editas, Dr. Burkly held positions of increasing responsibility over a 37-year tenure at Biogen, most recently leading neuroscience-focused research teams as Vice President and Senior Distinguished Investigator from 2014 to 2022. At Biogen, Dr. Burkly invented a novel anti-CD4 mAb that was developed into Trogarzo(R), discovered novel VLA- 4/VCAM biology and uses of VLA-4 blockers including for Crohn's disease, an indication of Tysabri(R), and was Biogen lead on a partnered collaboration with UCB and therein an inventor of Dapirolizumab.Dr. Burkly holds a Ph.D. from Tufts University Graduate School of Biomedical Sciences, Boston, MA, and a B.S. from Fairfield University. She completed a Postdoctoral Fellowship in the laboratory of Richard A. Flavell, Biogen Research Corp.
Positions
- Company NameEditas Medicine, Inc.Stock CodeEDITPositionExecutive VP & Chief Scientific Officer
